Literature DB >> 8580000

Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma.

M Kuliszkiewicz-Janus1, S Baczyński.   

Abstract

31P NMR spectra were obtained from sera of 22 healthy volunteers and 20 patients with multiple myeloma at the time of diagnosis and repeated up to five times during therapy. All spectra consisted of a Pi peak (used as a reference peak) and two peaks from phospholipids (PL): one peak due to phosphatidylethanolamine and sphingomyelin (PE + SM) and a second peak due to phosphatidylcholine (PC). Prior to therapy, peak intensities of the phospholipids were low relative to Pi. During therapy leading to remission, the resonance from PL progressively increased to approximate the spectral pattern seen in normal sera. By contrast, in non-responders an opposite trend was noted: the intensities of the phospholipid peaks became progressively reduced or remained unchanged. Long-term follow-up studies showed a good correlation between this 31P MRS evaluation of sera and the response of the disease to the therapy. In addition to the correlation with tumor response, our studies also show significant correlations between area, intensities of peaks of PE + SM, PC, and the concentrations of high-density lipoprotein (HDL) (correlation coefficients 0.46, 0.43, 0.59, respectively; p < 0.001). We found that the concentration of HDL in serum of patients with multiple myeloma was significantly reduced. In individuals responding to therapy HDL levels increased to the point where there were no statistically significant differences between them and healthy volunteers. In patients not responding to therapy, HDL concentration did not increase.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580000     DOI: 10.1002/nbm.1940080308

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  6 in total

1.  Abnormal serum lysophospholipids in multiple myeloma patients.

Authors:  T Sasagawa; M Okita; J Murakami; T Kato; A Watanabe
Journal:  Lipids       Date:  1999-01       Impact factor: 1.880

2.  Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.

Authors:  Alessia Lodi; Stefano Tiziani; Farhat L Khanim; Ulrich L Günther; Mark R Viant; Gareth J Morgan; Christopher M Bunce; Mark T Drayson
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

3.  Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma.

Authors:  C Ludwig; D S Williams; D B Bartlett; S J Essex; G McNee; J W Allwood; E Jewell; A Barkhuisen; H Parry; S Anandram; P Nicolson; C Gardener; F Seymour; S Basu; W B Dunn; P A H Moss; G Pratt; D A Tennant
Journal:  Blood Cancer J       Date:  2015-10-16       Impact factor: 11.037

Review 4.  Sphingomyelin in high-density lipoproteins: structural role and biological function.

Authors:  Roberto Martínez-Beamonte; Jose M Lou-Bonafonte; María V Martínez-Gracia; Jesús Osada
Journal:  Int J Mol Sci       Date:  2013-04-09       Impact factor: 5.923

5.  In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma.

Authors:  F Süllentrop; J Hahn; D Moka
Journal:  Int J Biomed Sci       Date:  2012-06

6.  Lipid changes occuring in the course of hematological cancers.

Authors:  Małgorzata Kuliszkiewicz-Janus; Rafał Małecki; Abdulrahman Saeed Mohamed
Journal:  Cell Mol Biol Lett       Date:  2008-05-06       Impact factor: 5.787

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.